Docoh
Loading...

STAA Staar Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or 'ICL', which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.discovericl.com. Headquartered in Lake Forest, CA, the company operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland.

Company profile

Ticker
STAA
Exchange
Website
CEO
Caren Mason
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
STAAR SURGICAL COMPANY
SEC CIK
IRS number
953797439

STAA stock data

(
)

Calendar

5 May 21
30 Jul 21
1 Jan 22
Quarter (USD)
Apr 21 Jan 21 Oct 20 Jul 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Jan 21 Jan 20 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jul 21 Broadwood Partners Common Stock Other Dispose J Yes No 0 0 0 8,663,584
1 Jul 21 Broadwood Partners Common Stock Other Dispose J No No 0 655 0 8,663,584
24 Jun 21 Farrell Stephen C Common Stock Option exercise Aquire M No No 0 404 0 6,212
24 Jun 21 Farrell Stephen C Common Stock Options Common Stock Option exercise Aquire M No No 154.96 850 131.72K 850
24 Jun 21 Frinzi Thomas G Common Stock Grant Aquire A No No 0 807 0 2,924
24 Jun 21 Kliman Gilbert H Common Stock Grant Aquire A No No 0 404 0 2,985
24 Jun 21 Kliman Gilbert H Common Stock Options Common Stock Option exercise Aquire M No No 154.96 850 131.72K 850
24 Jun 21 Lou Silverman Common Stock Option exercise Aquire M No No 0 807 0 2,924

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 226 195 +15.9%
Opened positions 63 34 +85.3%
Closed positions 32 17 +88.2%
Increased positions 64 58 +10.3%
Reduced positions 73 73
13F shares
Current Prev Q Change
Total value 5.46B 3.15B +73.3%
Total shares 51.9M 39.79M +30.4%
Total puts 394.7K 266.7K +48.0%
Total calls 498.5K 519.6K -4.1%
Total put/call ratio 0.8 0.5 +54.3%
Largest owners
Shares Value Change
Broadwood Partners 9.9M $1.03B NEW
Broadwood Capital 9.54M $1.01B -11.6%
BLK Blackrock 5.54M $584.09M +57.6%
Vanguard 4.52M $476.03M +7.6%
Baillie Gifford & Co 4.17M $439.65M +77.7%
Palo Alto Investors 1.81M $191.2M -36.3%
STT State Street 1.45M $152.8M +46.5%
Geneva Capital Management 934.97K $98.56M -27.1%
Geode Capital Management 792.31K $83.52M +11.2%
Ensign Peak Advisors 731.06K $77.06M +7.6%
Largest transactions
Shares Bought/sold Change
Broadwood Partners 9.9M +9.9M NEW
BLK Blackrock 5.54M +2.03M +57.6%
Baillie Gifford & Co 4.17M +1.82M +77.7%
Broadwood Capital 9.54M -1.25M -11.6%
Palo Alto Investors 1.81M -1.04M -36.3%
STT State Street 1.45M +460.16K +46.5%
Norges Bank 0 -459.86K EXIT
Geneva Capital Management 934.97K -348.27K -27.1%
Vanguard 4.52M +320.73K +7.6%
E Fund Management 301.65K +301.65K NEW

Financial report summary

?
Management Discussion
  • Net sales for the three months ended April 2, 2021 were $50.8 million, an increase of 44% from $35.2 million reported during the same period of 2020.  The increase in net sales was due to increased ICL sales of $17.2 million, partially offset by a decrease in other product sales of $1.6 million.  Changes in foreign currency favorably impacted net sales by $1.2 million.
  • Total ICL sales for the three months ended April 2, 2021 were $46.5 million, an increase of 58% from $29.3 million reported for the same period of 2020, with unit increase of 54%. The APAC region sales increased by 62%, with unit growth up 59%, due to sales growth in Japan up 77%, China up 67%, India up 65%, other APAC Distributors up 47%, and Korea up 32%.  The Europe, Middle East, Africa and Latin America region sales increased 51% with unit increase of 38%, due to sales growth in Distributor Operations up 71%, Germany up 58%, Latin America up 59% and Spain up 55%.  The North America region sales increased 44%, with unit increase of 49%, due increased sales in Canada up 60% and the U.S. up 42%.  First quarter 2021 sales growth continues to follow the third and four quarter 2020 sales growth trends experienced after the initial COVID-19 pandemic closures occurred in many of our primary markets during the first half of 2020. Changes in foreign currency favorably impacted ICL sales by $1.0 million for the three months ended April 2, 2021.  ICL sales represented 91.6% and 83.4% of our total sales for the three months ended April 2, 2021 and April 3, 2020, respectively.
  • Other product sales, including IOLs were $4.3 million for the three months ended April 2, 2021, a decrease of 27% from $5.8 million reported for the same period of 2020.  The decrease was due to product yield issues requiring rework related to preloaded injector parts manufactured on our behalf by a third-party vendor then sold by us to a third-party manufacturer for product they sell to their customers, as well as decreased IOL sales.  Changes in foreign currency favorably impacted other product sales by $0.2 million for the three months ended April 2, 2021.  Other product sales represented 8.4% and 16.6% of our total sales for the three months ended April 2, 2021 and April 3, 2020, respectively.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: Amir, Asia, behalf, bringing, CAA, Caren, complaint, counsel, Deborah, deferral, destination, dismissal, dismissed, disseminate, eligibility, enrichment, expanded, expanding, failing, Farrell, fiduciary, funding, housing, Injury, intraperiod, John, Leave, Mason, misleading, momentum, Moore, opened, oversee, overstating, Paid, Patrick, Paycheck, plaintiff, prejudice, Program, properly, respond, restitution, Retention, rework, round, Sick, Silverman, Sitabkhan, slightly, sought, Stephen, stipulation, stockholder, unjust, voluntary
Removed: accrue, amortized, approved, August, clarify, debt, enrollment, evaluating, expansion, factor, FASB, formed, fourth, holding, ii, improve, intra, issued, June, Kingdom, law, longer, measured, Measurement, month, note, permitted, pertaining, post, previously, recording, released, Requirement, retirement, reversed, reviewed, revised, significantly, sponsor, standard, submission, Subsequently, Subtopic, UK, updated, utilizing, withholding